SCHEMBL6070037

SCHEMBL6070037

O=C(O)[C@H]1O[C@@H]1C(=O)NCc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.54
HPGD P15428 3/20 0.54
MC4R P32245 2/20 0.54
USP2 O75604 1/20 0.54
TSHR P16473 3/20 0.54
HSD17B10 Q99714 1/20 0.54
LMNA P02545 2/20 0.53
HTT P42858 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C19 P33261 1/20 0.49
TP53 P04637 1/20 0.47
GAA P10253 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
MEN1 O00255 1/20 0.46
MAPT P10636 1/20 0.46
KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11167965 1.00 ALDH1A1 (0.54) ALDH1A1HPGDMC4RUSP2TSHR
SCHEMBL6069261 1.00 ALDH1A1 (0.54) ALDH1A1HPGDMC4RUSP2TSHR
SCHEMBL11166155 0.98 ALDH1A1 (0.53) ALDH1A1HPGDMC4RUSP2TSHR
SCHEMBL15171334 0.87 HSD17B10 (0.46) ALDH1A1HPGDMC4RUSP2TSHR
Potassium Ion SCHEMBL11166150 0.85 MC4R (0.54) ALDH1A1HPGDMC4RUSP2TSHR
SCHEMBL6070481 0.83 TAAR1 (0.56) ALDH1A1HPGDMC4RGAAL3MBTL1
SCHEMBL7763466 0.83 TAAR1 (0.56) ALDH1A1HPGDMC4RGAAL3MBTL1
SCHEMBL7763461 0.83 TAAR1 (0.56) ALDH1A1HPGDMC4RGAAL3MBTL1
SCHEMBL15937066 0.83 ALDH1A1 (0.54) ALDH1A1HPGDMC4RUSP2TSHR
SCHEMBL11183404 0.82 HPGD (0.47) ALDH1A1HPGDMC4RUSP2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7056947-B2 For inhibiting (cysteine) proteases/caspases; for treatment of viral infections, stroke, neurodegenerative disease, and inflammatory diseases GEORGIA TECH RESEARCH CORP. (US) 2006-06-06 US disclosed
US-20040048327-A1 Aza-peptide epoxides NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-03-11 US disclosed
WO-2004005270-A1 AZA-PEPTIDE EPOXIDES GEORGIA TECH RESEARCH CORPORATION (US) 2004-01-15 WO disclosed
EP-0808839-B1 EPOXYSUCCINAMIDE DERIVATIVES OR SALTS THEREOF, AND DRUGS CONTAINING THE SAME TAIHO PHARMACEUTICAL CO LTD (JP) 2001-05-23 EP disclosed
US-5883121-A INHIBITING ACTIVITY AGAINST CATHEPSIN, AND IS USEFUL FOR PREVENTION AND TREATMENT OF OSTEOPATHY SUCH AS OSTEOPOROSIS TAIHO PHARMACEUTICAL CO., LTD. (JP) 1999-03-16 US disclosed
EP-0808839-A1 EPOXYSUCCINAMIDE DERIVATIVES OR SALTS THEREOF, AND DRUGS CONTAINING THE SAME TAIHO PHARMACEUTICAL CO., LTD. (JP) 1997-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048327-A1 Aza-peptide epoxides ANPEP, ENPEP, TMPRSS15 ALDH1A1 1762/4885HPGD 282/4885MC4R 4095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.